The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Heart attacks are usually caused by clots in a coronary artery, depriving the heart muscle of
 blood. Platelets are the main type of blood cell causing clots to form and physicians
 typically give a combination of two anti-platelet drugs, aspirin and ticagrelor, to treat
 this. However, aspirin and ticagrelor have effects not just on the platelets but also on the
 immune system. The investigator has been investigating the effects of different doses of
 aspirin in heart attack participants when taken alongside ticagrelor, and have found that a
 new, lower dose of aspirin given twice daily, rather than the usual standard dose once daily,
 reduces the tendency to bleed whilst on treatment. The investigators are hoping to study the
 wider effects of different aspirin doses, with and without ticagrelor, and have therefore
 developed this study.

 During the two periods of the study, the investigator will give healthy volunteers a
 combinations of these medications and then stimulate their immune system, in order to see if
 the medications affect the immune response. The study will involve a period of medication for
 10-14 days followed by a day in hospital stimulating the immune system with an injection into
 the bloodstream of a substance known as endotoxin, which causes temporary flu-like symptoms,
 followed by blood and urine tests. The investigator will then repeat the process, after a
 minimum of five weeks, taking a different medication combination and having a further
 endotoxin injection. The investigator will also keep in contact by telephone until 2 weeks
 after the end of the medication to ensure participant remain well.
Potential participants will contact the research team in response to advertisement. the
 research team will then set up a screening appointment in the Clinical Research Facility
 (CRF) at the Northern general Hospital. They will be offered the chance to be sent a copy of
 the Participant information sheet for the study before the screening appointment, otherwise
 they will receive on arrival to the CRF and will be given as much time as they would like to
 read this.

 At the screening appointment (visit 1), a medically qualified member of the research team
 will discuss with the potential participant the background, rationale, design, requirements
 and risk of the study. The potential participant will have chance to ask any questions they
 wish and their understanding of the key points will be checked. If they are then happy to
 sign the consent form, they will do so and the medically-qualified members of the research
 team taking consent will also sign this. The participant will receive a copy of the signed
 form for their records. Once written consent has been obtained, participants will be
 interviewed to obtain information about their demographic details, medical history and
 medications. They will undergo a physical examination, have their vital signs and
 height/weight recorded, and have blood drawn from a vein for safety tests.

 At visit 2, which should occur within 14 days of visit 1 but not before the results of the
 safety blood tests are known, ongoing consent, any new adverse events and medication changes
 will be recorded. Vital signs will be checked and physical examination performed. The
 research team will review the results of the safety blood tests and, in combination with
 information collected at visit 1, determine if the participant meets all the inclusion
 criteria and none of the exclusion criteria, and therefore whether they can proceed to
 randomisation, which will be performed using an electronic (online) system designed for this
 purpose, sealedenvelope.com.

 Participants will be randomised to receive one of the following 8 treatment regimens, for 10
 days, during the first period of the study:

 -  no drug

 -  Ticagrelor 180 milligrams (mg) as a loading dose on the last day

 -  Aspirin 20 mg BD

 -  Aspirin 20 mg BD, plus ticagrelor 180 mg as a loading dose on the last day

 -  Aspirin 75 mg once-daily (OD)

 -  Aspirin 75 mg, plus ticagrelor 180 mg as a loading dose on the last day

 -  Aspirin 300 mg OD

 -  Aspirin 300 mg OD, plus ticagrelor 180 mg as a loading dose on the last day

 Participants will receive the supply of study medication for the first period and will be
 instructed when to take this. Aspirin will be supplied as a soluble powder preparation in 100
 mg sachets that will be used to prepare 20 mg, 75 mg and 300 mg doses. If required by the
 study to take aspirin, they will be trained in preparing the correct dose, provided with
 written illustrated instructions and appropriate equipment for this. They will have blood
 drawn and urine collected for baseline tests, and will undergo measurements of the bleeding
 time, whereby an inflatable cuff (of the type used for measuring blood pressure) is inflated
 to a low pressure around the arm, 3 small cuts in the skin of the forearm are made using
 sprung lancets designed to minimise discomfort, and the time taken for the cuts to stop
 bleeding is measured.

 Participants will then take their allocated study treatment for 10-14 days (medication period
 1), and will be asked not to take this on the morning of visit 3.

 At visit 3, which occur after 10-14 days of study medication, participants will once again
 attend the CRF, this time for a full day. Ongoing consent, any new relevant adverse events
 and medication changes will be recorded. Participants will undergo physical examination and
 check of vital signs to ensure they remain well. An intravenous cannula (of the kind
 typically used for a 'drip') will be inserted into a vein in each arm. One cannula (cannula
 A) will be used for blood sampling and the other (cannula B) for injection/infusion
 throughout the course of the day. Blood will be drawn from cannula A for study tests,
 bleeding time will be measured and urine collected. Participants will then be asked to take
 the last dose of study medication for period 1, including, where specified by the protocol, a
 loading dose of ticagrelor administered in the form of 2 x 90 mg orodispersible tablets.
 Unused medication will be collected, counted and returned to the Northern General Pharmacy.

 30 minutes later, an infusion ('drip') of normal saline will be started through cannula B to
 ensure participants are well hydrated. This will continue for 3 hours and 30 minutes in
 total. 30 minutes into the infusion, vital signs will be checked, blood will be sampled from
 cannula A, bleeding time will be measured and an injection of a weight-adjusted dose of
 sterile bacterial endotoxin will be given through cannula B.

 Further blood for study tests will be drawn 0.5, 1, 1.5, 2, 3, 4 and 6 hours after the
 endotoxin injection. Urine will be collected 1, 2, 4 and 6 hours after the endotoxin
 injection, Bleeding time will be measured 3 hours after the endotoxin injection. From the
 time of endotoxin administration until 6 hours after it, participants will be connected to a
 continuous cardiac monitor, and vital signs will be checked at 0.5, 1, 1.5, 2, 3, 4 and 6
 hours after the endotoxin injection. Any reportable adverse events will be recorded
 throughout the day. At the end of the day (6 hours after endotoxin injection) if feeling well
 participants will be allowed home, but if there are any concerns arrangements will be made
 for them to stay later, if necessary overnight, within the CRF or a ward of the Northern
 General Hospital.

 The day after visit 3, participants will be contacted by telephone by a member of the
 research team (visit 4). Ongoing consent, any new relevant adverse events and medication
 changes will be recorded. If there are any concerns raised by the participant or investigator
 arrangements will be made for an in-person review by a medically qualified member of the
 research team in the CRF.

 There will then be a break in study medication of at least five weeks. This is to ensure that
 any effects of the endotoxin and/or study medication have completely worn off before the next
 stage of the trial. At 10-14 days after visit 3, participants will be contacted by telephone
 by a member of the research team (visit 4). Ongoing consent, any new relevant adverse events
 and medication changes will be recorded. If there are any concerns raised by the participant
 or investigator arrangements will be made for an in-person review by a medically qualified
 member of the research team in the CRF.

 At visit 6, participants will attend for a clinic visit in the CRF. Ongoing consent, new
 relevant events and medications changes will be recorded. Vital signs will be checked,
 physical examination performed and safety blood tests taken. A new set of medication will be
 provided to the participant, with appropriate training in aspirin dosing if needed. The
 medication that the participant will be asked to take for the next 10-14 days (medication
 period 2) will be determined by what they were allocated in medication period 1:

 -  If received no drug in period 1, to receive no aspirin in period 2 but receive a loading
 dose of 180 mg ticagrelor on the last day of period 2

 -  If received no aspirin but received a loading dose of 180 mg ticagrelor on the last day
 of period 1, to receive no drug in period 2

 -  If received aspirin 20 mg BD but no ticagrelor in period 1, to receive aspirin 20mg BD
 in period 2 plus a loading dose of 180 mg ticagrelor on the last day of period 2

 -  If received aspirin 20 mg BD plus a loading dose of 180 mg ticagrelor on the last day of
 period 1, to receive aspirin 20 mg BD and no ticagrelor in period 2.

 -  If received aspirin 75 mg OD but no ticagrelor in period 1, to receive aspirin 75 mg OD
 in period 2 plus a loading dose of 180 mg ticagrelor on the last day of period 2

 -  If received aspirin 75 mg OD plus a loading dose of 180 mg ticagrelor on the last day of
 period 1, to receive aspirin 75 mg OD and no ticagrelor in period 2.

 -  If received aspirin 300 mg OD but no ticagrelor in period 1, to receive aspirin 300 mg
 OD in period 2 plus a loading dose of 180 mg ticagrelor on the last day of period 2

 -  If received aspirin 300 mg OD plus a loading dose of 180 mg ticagrelor on the last day
 of period 1, to receive aspirin 300 mg OD and no ticagrelor in period 2.

 Participants will then take their allocated study treatment for 10-14 days (medication period
 2) and will be asked not to take this on the morning of visit 7.

 Visits 7, 8 and 9 will be another full day visit to the CRF followed by a telephone call the
 next day and after 10-14 days. These will follow exactly the same process as visit 3, 4 and
 5. At this point their involvement in the study will end and they will be thanked for their
 participation.
Inclusion Criteria:

 -  Healthy male subjects, or female subjects not of childbearing potential (either
 surgically sterile or post-menopausal)]

 -  Age between 18 and 65 years inclusive

 -  Non-smokers

 -  Body mass index (BMI) between 18 and 28 kg/m2 inclusive, with a body weight between
 60-100 kg

 -  In good health as determined by a medical history, physical examination, vital signs
 and clinical laboratory test results, including renal and liver function, and full
 blood count

 -  Provision of informed consent before any trial-related activity

 Exclusion Criteria:

 -  Any history of cancer, diabetes or, in the opinion of the investigator,
 clinically-significant cardiovascular, respiratory, metabolic, renal, hepatic,
 gastrointestinal, haematological, dermatological, neurological, psychiatric or other
 major disorders

 -  Any history of either significant multiple drug allergies or known allergy to the
 study drugs or any medicine chemically related to the study drugs

 -  A clinically-significant illness within 4 weeks of randomisation

 -  Any clinically-significant abnormal laboratory test results at screening in the
 opinion of the investigator

 -  A supine blood pressure at screening, after resting for 5 minutes, higher than 150/90
 mmHg or lower than 105/65 mmHg

 -  A supine heart rate at screening, after resting for 5 minutes, outside the range of
 50-100 beats/min

 -  Receipt of any prescribed or over-the-counter systemic or topical medication within 48
 hours prior to the start of dosing

 -  Planned or expected requirement, during the next 3 months (at randomisation, or 3
 weeks at the start of period 2), for any systemic or topical prescribed drug, or for
 systemic or topical over-the-counter NSAID, corticosteroid, anthihistamine or any
 other drug that could affect inflammation, thrombosis or haemostasis in the opinion of
 the investigator.

 -  Receipt of an investigational medicinal product within the previous four months (new
 chemical entity) or three months (licensed product) or subjects who have received a
 vaccine within three months preceding the start of dosing. When reconfirming
 eligibility at the start of period 2, receipt of aspirin, ticagrelor or endotoxin
 during period 1 of this study will not be counted for this purpose.

 -  Any donation of blood or plasma in the month preceding the start of dosing.

 -  A history of alcohol or drug abuse

 -  Mental incapacity or language barriers that preclude adequate understanding